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Abstract  
Background: Perinatally-acquired HIV infection commonly causes stunting in children; how 
this affects bone and muscle development is unclear. We investigated differences in bone 
and muscle mass and muscle function between children with HIV (CWH) and uninfected 
children.  
Setting: Cross-sectional study of CWH (6–16 years) receiving antiretroviral therapy (ART) for 
>6 months and similar aged children testing HIV-negative at primary health clinics in 
Zimbabwe.  
Methods: From Dual-energy X-ray Absorptiometry (DXA) we calculated total-body less-head 
(TBLH) Bone Mineral Content (BMC) for lean mass adjusted-for-height (TBLH-BMCLBM) Z-
scores, and lumbar spine (LS) Bone Mineral Apparent Density (BMAD) Z-scores.  
Results: The 97 CWH were older (mean age 12.7 vs. 10.0 years) and taller (mean height 
142cm vs. 134cm) than 77 uninfected. However, stunting (height-for-age Z-score≤-2) was 
more prevalent in CWH (35% vs. 5%, p<0.001). Amongst CWH, 15% had low LS-BMAD (Z-
score ≤-2) and 13% low TBLH-BMCLBM, vs. 1% and 3% respectively in those uninfected (both 
p≤0.02). After age, sex, height and puberty adjustment, LS-BMAD was 0.33 SDs (95%CI -0.01, 
0.67; p=0.06) lower in CWH, with no differences by HIV status in TBLH-BMCLBM, lean mass 
(0.11 [-0.03, 0.24], p=0.11) or grip strength (0.05 [-0.16, 0.27], p=0.62). However, age at ART 
initiation was correlated with both LS-BMAD Z-score (r=-0.33, p=0.001) and TBLH-BMCLBM Z-
score (r=-0.23, p=0.027); for each year ART initiation was delayed a 0.13 SD reduction in LS-
BMAD was seen.  
Conclusion: Size-adjusted low bone density is common in CWH. Delay in initiating ART 
adversely affects bone density. Findings support immediate ART initiation at HIV diagnosis. 
Keywords: DXA; Bone density; Stunting; ART; Tenofovir; children. 
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Introduction 
In 2017, globally, up to 1.8 million children were living with HIV 1,  90% in sub-Saharan Africa 
where HIV remains the leading cause of death 2. The scale-up of antiretroviral therapy (ART) 
has dramatically improved survival for children living with HIV 3; changing the infection from 
one that was almost invariably fatal to a chronic treatable, but incurable, condition. 
However, even in the era of ART, children experience a range of multisystem morbidities 
due to their infection and/or their treatment 4. 
  
Growth failure, e.g. stunting (poor linear growth), is one of the most common 
manifestations of perinatally-acquired HIV infection, affecting up to 50% of children 5. 
However, the impact on bone development in children is not well understood. A recent 
systematic review of bone health identified a high prevalence of low bone mass (when bone 
mass is two or more standard deviations [SD] below that expected for age) in children and 
adolescents living with HIV in high income countries (HICs), but found no studies from low 
income countries (LICs) 6. Importantly, a one SD reduction in bone mass is associated with a 
doubling in childhood fracture risk, in otherwise healthy children 7. In addition, adolescence 
is a crucial period of bone mass accrual, with peak bone mass (PBM) achieved at the end of 
skeletal maturation. Low PBM is a critical determinant of subsequent adult osteoporotic 
fracture risk 8; a 10% reduction in PBM doubles fracture risk in adulthood 9,10. 
 
Muscle strength and bone strength are closely related; muscles exert forces on bone 
resulting in bone adaptation in size and strength 11. HIV infection and consequent ill-health 
may result in reduced physical activity, which in turn may impair muscle strength and 
skeletal impact loading, impairing bone development 12-14. Furthermore, ART may itself 
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adversely affect bone and muscle health 15,16. Few studies have compared muscle strength 
and function between HIV infected and uninfected children 13 . If greater muscle strength 
predicts higher bone mass, then physical activity interventions could potentially optimise 
musculoskeletal health. 
 
The aim of this study was to determine the prevalence of low bone density among children 
with HIV (CWH) in Zimbabwe, and factors associated with low bone density, after 
accounting for body size. We further aimed to establish whether lean muscle mass and 
function are lower among CWH than uninfected peers, and whether muscle measures might 
explain any differences seen in size-adjusted bone density. 
 Page 5 of 29 
 
Methods 
A cross-sectional study was conducted between July 2016 and July 2017 at the paediatric 
HIV clinic at Harare Central Hospital, Zimbabwe. This is a public sector clinic that provides 
HIV care for more than 1,500 children. Children were eligible for the study if they were aged 
between 6 and 16 years, had been taking ART for at least 6 months, were not acutely unwell 
(no acute symptoms) and were not taking treatment for tuberculosis. Up to five eligible 
participants were consecutively recruited per day, restricted to this number due to logistical 
constraints. Children were convenience sampled within logistical and budgetary constraints. 
A comparison group of HIV-uninfected children in the same age group was recruited from 
seven primary care clinics that provided opt-out HIV testing and counselling to all attendees 
regardless of the reason for attendance, and that served the same catchment population as 
that of Harare Central Hospital. Children who tested HIV negative, were not acutely unwell 
and were not receiving treatment for tuberculosis were enrolled. 
 
Data collection 
A nurse-administered questionnaire was used to collect socio-demographic data, clinical 
history including age at HIV diagnosis and ART initiation, ART regimen, history of menarche 
and voice breaking. Where possible, clinical history was confirmed with documentation 
within patient hand-held medical records. A standardized examination was performed 
including WHO staging of HIV infection and measurement of height and weight using 
SECA® height board and electronic SECA® weighing scales (Seca United Kingdom, 
Birmingham, England) and Tanner pubertal stage using standardised protocols and 
calibrated equipment. Hand grip strength in kilograms was measured using a Jamar 
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hydraulic hand-held dynamometer (Patterson Medical, UK). Participants were seated with 
the shoulder at 0° to 10°, the elbow at 90° of flexion and the forearm positioned neutrally 17. 
Three measurements were taken from each hand in alternation by trained staff, and the 
highest measurement from the six taken was used in analyses. Age and CD4 count at 
diagnosis were collected from hand held medical records and based on guardian report if no 
record was available. 
 
Dual-energy X-ray absorptiometry measurements 
Dual X-ray absorptiometry (DXA) scans were performed by two trained radiographers using 
standard procedures on a Hologic QDR Wi densitometer (Hologic Inc., Bedford, MA, USA) 
with Apex Version 4.5 software for scan analysis. Daily calibration was conducted using a 
manufacturer provided spine phantom. Lumbar spine (LS) and Total body (TB) scans were 
performed from which BMC (Bone Mineral Content), and TB fat mass were measured, TB 
lean mass calculated as fat-free mass, and areal BMD (Bone Mineral Density) calculated 
(repeated phantom measures generated coefficients of variation <0.5%). DXA calculates 
two-dimensional (areal) BMD which is highly dependent upon bone size 18-20 and is 
therefore unsuitable for use in growing children; DXA underestimates BMD when bones are 
small 21. Therefore, size adjustment techniques, as recommended by the International 
Society for Clinical Densitometry (ISCD) 22, were used to measure bone mineral apparent 
density (BMAD) Z-score at the lumbar spine and regression-based total-body less-head 
(TBLH) Bone Mineral Content (BMC) for lean mass adjusted for height (TBLH-BMCLBM) Z-
score, using, in the absence of African reference datasets, the recommended age and 
gender specific reference data derived from growth curves for white children in the  UK (the 
ALPHABET dataset: Amalgamated Reference Data for Size‐Adjusted Bone Densitometry 
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Measurements in Children and Young Adults) 23. Total body-less-head (TBLH) BMC, which is 
considered one of the most accurate and reproducible methods in children, was measured  
22. Then Z-scores for TBLH-BMC adjusted for Lean Body Mass, fat mass and height (BMCLBM) 
were generated from ALPHABET regression-derived reference growth curves 23. The head is 
excluded as it represents a greater proportion of skeletal mass in younger children and may 
obscure important skeletal deficits. Furthermore, the head is not weight-bearing and does 
not grow in response to factors like physical activity 22. Low LS-BMAD and low TBLH-BMCLBM 
were both defined as a Z-score ≤ -2, according to recommended clinical definitions22. 
 
Laboratory Investigations 
Among CWH, HIV viral load was measured using COBAS Ampliprep/Taqman 48 Version 2.0 
(Roche, Rotkreuz, Switzerland) and CD4 cell count was measured using an Alere PIMA CD4 
(Waltham, Massachusetts, USA) machine. 
 
Ethical approval 
Ethical approval was granted by the Medical Research Council of Zimbabwe (MRCZ/A/1856), 
the Harare Hospital Ethics Committee, the Biomedical Research and Training Institute 
Institutional Review Board (AP125) and the London School of Hygiene and Tropical Medicine 
Ethics Committee (8263). All guardians gave written consent, and participants gave written 
assent to participate in the study. 
 
Data analysis 
Data were extracted from paper forms using optical character recognition software (Cardiff 
TELEFORM Intelligent Character, Version 10.7; Hewlett Packard, Palo Alto, California, USA). 
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Data analysis was carried out using Stata v13 (StataCorp, College Station, Texas, USA). 
Height-for-age and body mass-for-age Z-scores were calculated using the WHO reference 
standards 24. 
 
Continuous variables were summarised as mean (standard deviation: SD) and median (inter-
quartile range: IQR), and categorical variables as counts (percentages). Multivariable linear 
regression models were used to examine the differences in bone and muscle measures 
between participants with and without HIV infection. Continuous outcome variables were 
standardized for regression analyses, so that differences are presented, with 95% 
confidence intervals (95% CI), as the number of SDs difference between HIV infected and 
uninfected participants. Serial adjustments to differences in bone and muscle measures 
were decided a priori; model 1: adjusted for age and sex, model 2: adjusted for age, sex, 
height (categorised), model 4: adjusted for age, sex, height (categorised by 10cm increments 
to account for any non-linearity), and puberty. As Hologic derived TBLH-BMCLBM takes 
account of lean mass and height, these were not adjusted for further in TBLH-BMCLBM 
models. Modification of the effect of age at ART initiation by tenofovir use on bone 
outcomes, of lean mass and muscle function by HIV status on bone outcomes, and of age at 
the time of DXA by HIV status on bone and muscle outcomes, were investigated by fitting 
appropriate interaction terms to linear regression models. In addition, we calculated 
correlation coefficients for figures comparing two linear variables. 
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Results 
A total of 97 CWH and 77 uninfected participants were recruited, of whom 52% were 
female. Participants with HIV were older than those uninfected, mean (SD) 12.7 (2.5) vs. 
10.0 (2.9) years, and hence were taller and heavier (Table 1). A high proportion of CWH 
were stunted compared to those uninfected (32% vs. 5%, p<0.001). All CWH were infected 
perinatally, and 22% of HIV-uninfected individuals reported having a mother with HIV. 
 
The 97 CWH had a median age at diagnosis of 4 years (IQR 2-7) (Table 2). The median age at 
initiation of ART was 5.9 years (IQR 3.2-8.4) and 44 (46%) reported past or current tenofovir 
use. At enrolment, 79% were virologically supressed (HIV viral load <400 copies/ml) and the 
median CD4 count was 733 (IQR 473-983) cells/mm3. Only one child with HIV reported a 
prior history of an arm fracture. 
 
Bone density 
Low LS-BMAD (i.e. a Z-score ≤-2) was more common among CWH than those uninfected, 
15% vs. 1% (p=0.002); the same was true for low TBLH-BMCLBM found in 13% vs. 3%, p=0.018 
(Table 1). Among CWH, there was no association between stunting, defined as a height-for-
age (HFA) Z-score <-2, and of low BMAD at the lumbar spine (p value= 0.36) or of low TBLH-
BMCLBM (p value= 0.81). 
 
Initially, in unadjusted analyses, CWH appeared to have higher lumbar spine BMC than 
uninfected individuals (Table 1), but when comparing BMAD, which takes account of body 
size, this difference was no longer observed (Table 1).  However, when then comparing 
BMAD Z-scores, which standardises for age and gender, the LS-BMAD Z-scores were 
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significantly lower in CWH compared to uninfected children (mean -0.742 vs. -0.093, 
p<0.001) (Table1). Similar patterns were seen in the TBLH after taking account of body size 
and after standardisation for age and gender, with a mean TBLH-BMCLBM Z-score of -0.643 in 
CWH compared to Z-score -0.314 in those uninfected, p=0.045. After adjustment for age, 
sex, height and puberty, a difference was still seen in LS-BMAD between CWH and 
uninfected children, such that the mean difference was 0.33 SDs (95% CI -0.01, 0.67; 
p=0.055) lower in CWH compared to those without HIV, whilst no clear difference  in TBLH-
BMCLBM [0.26 SDs (95% CI -0.09, 0.61; p=0.148)] was observed between CWH and those 
without HIV. 
 
In CWH, there was a concerning inverse association between age and LS-BMAD Z-Score, and 
to a lesser extent TBLH-BMCLBM Z-Score (Figure 1, unadjusted). This contrasted with the 
stable LS-BMAD and TBLH-BMCLBM Z-Scores seen across all ages among children without 
HIV. This suggests that older CWH are more likely to have a low LS-BMAD in comparison 
with their peers without HIV. In support of this, there was modification of the effect of age 
on LS-BMAD Z-score by HIV status (interaction p=0.03). 
 
Bone density and HIV treatment 
Age at ART initiation was associated with both TBLH-BMCLBM Z-score and LS-BMAD Z-score, 
such that for each year ART initiation was delayed, there was a 0.08 SD reduction in TBLH-
BMCLBM and 0.13 reduction in LS-BMAD (Figure 2). This means that those children starting 
ART after the age of 8 years had on average, at least a 1 SD reduction in LS-BMAD compared 
with the reference population. There was no modification of this effect by the use of 
tenofovir as part of the ART regimen (p=0.37), but numbers were small (Supplementary 
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Figure 1). Those who took tenofovir had a significantly lower LS-BMAD Z-scores than those 
who had not received tenofovir (mean [SD] -1.14 [1.28] vs. -0.44 [1.23], p=0.008); a less 
marked difference was seen for TBLH-BMCLBM Z-Score (-0.90 [1.02], vs. -0.46 [1.28], 
p=0.072). 
 
Muscle Mass & Function 
Age was positively associated with lean mass and with muscle function (grip strength), in 
both CWH and children without HIV, although uninfected children demonstrated a stronger 
association between age and lean mass, than did CWH (interaction p=0.008) (Figure 1). The 
greater body weight measured among CWH compared to those children without HIV was 
explained by a higher relative proportion of lean mass, rather than increased fat mass (Table 
1). Correspondingly, muscle function, measured as maximal grip strength, was found to be 
greater among CWH than those uninfected; however, after adjusting for age and sex, no 
difference in muscle function was observed (Table 3). After similar adjustment, CWH had a 
lower lean mass than those who were uninfected, but this was explained by differences in 
height and pubertal stage between the two groups (Table 3). No clear relationships were 
seen between either lean mass or muscle function and TBLH-BMCLBM or LS-BMAD Z-scores, 
in participants with or without HIV (Supplementary Figure 2). 
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Discussion 
Our study showed that low size-adjusted bone density is common among CWH, the majority 
of whom were pre-pubertal. This low bone density was observed in both trabecular-rich 
skeletal sites (i.e. 15% having low lumbar spine BMAD) and cortical-rich sites (i.e. 13% 
having low TBLH-BMCLBM). Importantly, the age at ART initiation was a key predictor of 
lumbar spine bone density, such that children starting ART after the age of 8 years had on 
average, at least a 1 SD reduction in lumbar spine BMAD compared with the reference 
population. This is a clinically important effect size, as it is thought that a 1 SD reduction in 
bone density doubles both childhood and, if sustained, future adult fracture risk 7,25. Given 
the recent report that current median age of ART initiation in Sub-Saharan Africa is 7.9 years 
26, the extrapolation that potentially half of such children may be at significant increased 
fracture risk is of concern. There was also evidence of lower bone density, particularly in 
trabecular-rich skeletal sites, in those children treated with tenofovir as part of their ART 
regimen. In Zimbabwe tenofovir forms part of the first-line ART regimen in children aged 12 
years or older and/or who weigh 35kgs or more. Hence, our findings from a relatively young 
population, with a relatively short duration of tenofovir exposure, may underestimate any 
effect of tenofovir on the growing skeleton. These findings are consistent with several 
studies in adults 27; however, data from children have been less consistent 28 and 
longitudinal data in larger populations, including those in Sub-Saharan Africa, are needed to 
determine whether this association is transient or persists after treatment initiation.  
 
Our findings show that stunting is not a proxy for low size-adjusted bone density. 
Adolescent skeletal growth is not linearly and structurally uniform; peak height velocity 
precedes peak bone content accrual 29, yet how bone is accrued in the context of HIV 
 Page 13 of 29 
 
infection with associated delayed puberty, and hence skeletal maturation 30, is poorly 
understood. Despite CWH being on average 2.7 years older than those uninfected, only 14% 
more CWH had entered puberty. HIV infection is an established cause of pubertal delay and 
it is possible that some of the effect of HIV infection on size-adjusted bone density may be 
mediated through this mechanism 31,32. 
 
After accounting for body size and pubertal stage, no differences were seen in muscle mass 
or function between those with and without HIV infection. Furthermore, neither muscle 
mass or function were associated with bone density, suggesting that muscle is not affected 
in the same way as bone in the context of longstanding paediatric HIV infection. A small 
study of 15 Puerto Rican CWH were also found to have similar lower limb muscle strength to 
uninfected controls 33. Although, a more recent Canadian study which assessed lower limb 
muscle function by jumping mechanography, in a population 2 years older than ours (n=35), 
did find an albeit small difference in lower limb muscle power 13. Whether power rather 
than strength, or lower limb rather than upper limb function, may be affected by HIV 
infection remains to be determined. 
 
The Children with HIV Early Antiretroviral Therapy (CHER) trial showed substantially reduced 
mortality in infants with immediate ART initiation leading to recommendations that all 
infants with HIV should be treated with ART following diagnosis 34. There has been no such 
benefit demonstrated in older children 35,36 and until recently, guidelines for treatment 
eligibility for older children and adolescents were the same as those for adults, based on 
disease or immunological stage 37,38. The recent START and TEMPRANO trials both 
demonstrated that early initiation of ART reduced the risk of severe illnesses 39,40; these 
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trials were conducted in adults only and excluded older children and adolescents. Our 
findings add strong support to the recent WHO treatment guidelines which recommend 
prompt ART initiation following diagnosis of HIV infection regardless of clinical or 
immunological stage of infection in children 38. While these guidelines are a positive step 
towards improvement of health of CWH, there likely remains a cohort of children in Sub-
Saharan Africa who are missed by programmes to prevent mother-to-child transmission 
including early infant diagnosis and who will therefore be diagnosed in later childhood 41. 
Furthermore, children progressing through adolescence are at high risk of poor adherence 
and therefore inadequate viral suppression, which may put their bone health at risk 42. It 
remains to be seen whether improved ART roll-out will ameliorate this risk, or whether 
there will be a higher than expected fracture burden in the region in the future.   
 
Our study highlights the importance of using the ‘gold-standard’ size-adjustment 
methodology when conducting studies of bone density in the growing skeleton, particularly 
in the context of HIV where stunting is so common. Other strengths of this study are the 
prospective and (based on symptoms) unselected recruitment of participants. Until now, 
DXA-based studies in CWH in Sub-Saharan Africa have been limited to South Africa 43. DXA 
capacity is severely limited across the region 44, so that such studies are logistically 
challenging. Our study has limitations, including the cross-sectional nature of the study 
design which prevents causal inference, and the older age of the infected compared to 
uninfected participants which explain the height and weight differences seen, although our 
analyses enabled suitable adjustment. We lacked hand/wrist radiographs from which to 
derive bone age as a more accurate measure of skeletal maturation than chronological age 
adjusted for Tanner stage. We lacked data to permit analysis of differing ART regimes and 
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durations and their associations with weight, height and bone measurements. Notably, 22% 
of our uninfected children reported maternal HIV infection, hence these children may have 
been exposed but uninfected. It is unclear whether such children are at risk of impaired 
skeletal development, if so, this may have led us to underestimate the true magnitude of 
difference between CWH and uninfected (and unexposed) children. Furthermore, there is a 
global lack of bone density reference data for child/adolescent populations in Africa, which 
meant that following International Society for Clinical Densitometry (ISCD) guidance 22, we 
used the recommended age and gender specific reference data derived from white children 
in the UK 23. Future studies are needed to establish normative data for African populations. 
 
In conclusion, perinatally-acquired HIV infection is associated with both stunting and low 
lumbar spine bone density (adjusted for size) in Zimbabwean children, but importantly 
these conditions appear to be independent of one another. Such low bone density has been 
associated with substantially increased fracture risk in other populations. Our findings 
suggest delays in initiating ART contribute to lower bone density in CWH, and our findings 
support the current recommendations to initiate ART regardless of disease or 
immunological stage. Longitudinal data are needed from high HIV prevalence settings in 
Sub-Saharan Africa to establish how size-adjusted bone density changes through pubertal 
growth and following treatment of HIV infection, together with future fracture incidence 
studies. 
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Figure Legends 
 
Figure 1: Unadjusted relationships between age and TBLH-BMCLBM and LS BMAD Z-scores, 
lean muscle mass, grip strength, stratified by HIV status. Red unbroken line and squares 
indicate children with HIV (CWH). Blue dotted line and triangles indicate children without 
HIV infection. DXA, Dual energy X-ray Absorptiometry; TBLH-BMCLBM; total-body less-head 
Bone Mineral Content for lean mass adjusted for height; BMAD, Bone Mineral Apparent 
Density. 
 
Figure 2: Unadjusted relationships between age at ART initiation and TBLH-BMCLBM and 
Lumbar spine BMAD Z-scores among children with HIV. ART; Antiretroviral Therapy; TBLH-
BMCLBM; total-body less-head Bone Mineral Content for lean mass adjusted for height; 
BMAD, Bone Mineral Apparent Density. 
 
Supplementary Figure 1: Unadjusted relationships between age at ART initiation and TBLH-
BMCLBM and Lumbar spine BMAD Z-scores, stratified by the use of Tenofovir, among children 
with HIV. Red unbroken line and squares indicate children with HIV and a history of 
Tenofovir use. Blue dotted line and triangles indicate children with HIV without a history of 
Tenofovir use. ART; Antiretroviral Therapy; TBLH-BMCLBM; total-body less-head Bone 
Mineral Content for lean mass adjusted for height; BMAD, Bone Mineral Apparent Density. 
 
Supplementary Figure 2:  Unadjusted relationships between muscle mass and function and 
TBLH-BMCLBM and Lumbar spine BMAD Z-scores, stratified by HIV status. Red unbroken line 
and squares indicate children with HIV. Blue dotted line and triangles indicate children 
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without HIV. TBLH-BMCLBM; total-body less-head Bone Mineral Content for lean mass 
adjusted for height; BMAD, Bone Mineral Apparent Density. 
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Table 1: Characteristics of study participants by HIV status 
 HIV-positive 
(n=97) 
HIV-negative 
(n=77) 
p value 
General characteristics    
Mean (SD)   
Age at DXA scan, years  12.7 (2.5) 10.0 (2.9) <0.001 
Height, cm  141.5 (11.4) 134.0 (16.6) <0.001 
Weight, kg 35.2 (9.5) 31.1 (10.5) 0.007 
BMI, kg/m2  17.3 (2.6) 16.8 (1.9) 0.175 
N (%)   
Gender, female 51 (52.6) 40 (52.0) 0.934 
Puberty (menarche or voice broken) a 25 (26.0)b 11 (14.3) 0.058 
Mother known to be HIV infected  97 (100) 17 (22.1) <0.001 
Stunted (HFA Z-score <-2)  31 (32.0) 4 (5.2) <0.001 
Underweight (BFA Z-score <-2)  14 (14.4) 0 (0.0) 0.001 
DXA and grip strength characteristics   
Mean (SD)   
Maximal handgrip strength, kg 21.0 (8.2)c 16.2 (6.5)d <0.001 
TB Lean mass, kg  26.2 (6.3)e 23.0 (7.8) 0.003 
TB Fat mass, kg  9.1 (4.6)e 8.6 (3.7) 0.397 
TBLH-BMC, g 896.0 (262.7)e 789.0 (333.4) 0.019 
TBLH-BMCLBM Z-score -0.643 (1.189) -0.314 (0.882) 0.045 
L spine BMC, g  28.4 (8.9) 24.9 (11.4) 0.023 
L spine BMAD, g/cm2  0.196 (0.037) 0.195 (0.032) 0.801 
L spine BMAD Z-score  -0.742 (1.295)e -0.093 (0.886) <0.001 
N (%)   
Low TBLH-BMCLBM (Z-score ≤-2) 12 (12.5)e 2 (2.6) 0.018 
Low L Spine BMAD (Z-score <-2)  14 (14.6)e 1 (1.3) 0.002 
BMI, Body Mass Index; HFA, Height for Age; BFA, Body Mass for Age; SD, Standard 
Deviation; DXA, Dual energy X-ray Absorptiometry; TB, Total Body; TBLH, Total-Body Less 
Head; BMC, Bone Mineral Content; TBLH-BMCLBM; total-body less-head Bone Mineral 
Content for lean mass adjusted for height; BMAD, Bone Mineral Apparent Density; L spine, 
Lumbar Spine. 
a mean age at puberty 11.9 (2.6) years for CWH and 9.5 (2.9) years for children without HIV. 
16 girls with HIV had reached menarche at mean [SD] age 13.5 [2.5] years, compared with 7 
girls without HIV 13.2 [1.4] years. 
bn=96 CWH with data, cn=85. dn=71. en=96. 
Students t test for continuous data and χ2 test for categorical data (i.e. unadjusted) 
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Table 2: HIV-specific summary characteristics amongst the 97 children with HIV  
 Mean (SD) Median (IQR) 
Age at HIV diagnosis, years 4.7 (3.0) 4 (2-7) 
Time since HIV diagnosis a, years 8.1 (2.5) 8.1 (6.8-9.2) 
Age at ART initiation, years 6.2 (3.4) 5.9 (3.2-8.4) 
CD4 count at time of HIV diagnosis, cells/mm3b 459.9 (333.7) 386 (242-696) 
CD4 count at study recruitment, cells/mm3 764.0 (372.8) 733 (473-983) 
 N (%)  
Viral load suppressed <400 copies/ml 77 (79.4)  
ART regime ever included Tenofovirc  44 (45.8)  
DXA; Dual energy X-ray Absorptiometry, ART; Antiretroviral Therapy, SD; Standard 
Deviation; IQR, Inter-quartile Range. 
aat time of DXA scan. bn=47. c n=96. 
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Table 3: Differences in Lumbar Spine BMAD, TBLH-BMCLBM, muscle mass and muscle 
function between children with and without HIV infection, after serial adjustments 
 N Mean difference 
(95% CI) 
p value  
TBLH-BMCLBM    
     Model 1: age, sex 172 -0.30 (-0.64, 0.04) 0.088 
     Model 3*: age, sex, puberty  172 -0.26 (-0.61, 0.09) 0.148 
Lumbar spine BMAD    
     Model 1: age, sex 172 -0.41 (-0.73, -0.09) 0.011 
     Model 2: age, sex, height 172 -0.39 (-0.71, -0.06) 0.022 
     Model 3: age, sex, height, puberty  172 -0.33 (-0.67, 0.01) 0.055 
Lean Muscle Mass    
     Model 1: age, sex 172 -0.38 (-0.56, -0.20) <0.001 
     Model 2: age, sex, height 172 -0.16 (-0.29, -0.03) 0.019 
     Model 3: age, sex, height, puberty 172 -0.11 (-0.24, 0.03) 0.111 
Muscle grip strength    
     Model 1: age, sex 154 -0.10 (-0.31, 0.11) 0.353 
     Model 2: age, sex, height 154 -0.01 (-0.22, 0.20) 0.924 
     Model 3: age, sex, height, puberty 154 0.05 (-0.16, 0.27) 0.620 
BMAD; Bone Mineral Apparent density, TBLH-BMCLBM; total-body less-head Bone Mineral 
Content for lean mass adjusted for height. CI; Confidence interval. 
Model 1: adjusted for age and gender. Model 2: model 1 & height (as category). Model 3: 
model 2 & puberty. Model 3*: adjusted for age, gender and puberty. Mean differences are 
shown in SD units, negative Betas (mean difference values) indicate a lower measured 
outcome in the group with HIV infection. 
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Highlights 
 We studied 97 children living with HIV and 77 uninfected peers aged 6 to 16 and 
living in Harare, Zimbabwe 
 A high proportion of children with HIV were stunted (height-for-age Z-score <-2) 
compared to those uninfected (32% vs. 5%, p<0.001) 
 Low lumbar spine BMAD (Z-score ≤-2) was more common among children with HIV 
than those uninfected, 15% vs. 1% (p=0.002) 
 Low lumbar spine BMAD occurred independently of stunting, i.e. stunting is not a 
proxy for low size-adjusted bone density 
 Age when starting antiretroviral therapy predicted lumbar spine BMAD; with 1 SD 
lower BMAD when starting after age eight 
 After accounting for height and pubertal stage, muscle mass and strength were similar 
in children with and without HIV infection 
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